CytomX Therapeutics, a clinical-stage biopharmaceutical company based in South San Francisco, develops conditionally activated biologics for oncology, with a pipeline including CX-904 and CX-2051. The company went public on October 8, 2015, and has 120 employees.
Marcia Belvin sold 19,512 shares of CTMX on 18 March at $0.60 per share, worth a total of $12K. They now own 248,636 CTMX shares, or a 7% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
